Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Saved in:
| Title: | Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages. |
|---|---|
| Authors: | Ackerson BK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Bruxvoort KJ; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA., Qian L; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Sy LS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Qiu S; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Tubert JE; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Lee GS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Ku JH; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Florea A; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Luo Y; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Bathala R; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Stern J; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Choi SK; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Takhar HS; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Aragones M; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA., Marks MA; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Anderson EJ; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Zhou CK; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Sun T; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA., Talarico CA; Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA.; Epidemiology, AstraZeneca, Gaithersburg, MD, USA., Tseng HF; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2335052. Date of Electronic Publication: 2024 Apr 04. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
